Otlertuzumab

N/A

Report date: 2023/05/05 16:59:42

Base Information

Drug NameOtlertuzumab

Drug Alias NameTRU-016

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsLeukocyte antigen CD37 antagonists

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPolandAustria +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEmergent Aptevo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAptevo Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, T-Cell, PeripheralLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A